The Cooper Companies, Inc.
COOCooper’s strength comes from selling everyday medical products that patients reorder again and again.
Because boring, repeat purchases can be powerful wealth builders over 20 years.
Business Model
Devices plus services
It sells contact lenses and women’s health medical products to eye care professionals and clinics worldwide.
Economic Engine
High gross margins
A 60.7 percent gross margin shows strong pricing power at the product level.
Long-Term Lens
Healthcare durability
The key question is whether demand for vision and fertility care keeps compounding for decades.
On this page
Company Story
How do The Cooper Companies, Inc.'s business model and economics hold up on a closer read?
Start with the business itself, then go one layer deeper into the model, the economics, and the long-term case.
“A steady medical supplier riding lifelong vision and fertility demand, but long-term returns hinge on defending margins in a competitive device market.”
What does The Cooper Companies, Inc. actually do?
The Cooper Companies makes and sells contact lenses and women’s health medical devices used by doctors and patients every day.
- Produces soft contact lenses that people replace daily, biweekly, or monthly
- Sells fertility and women’s health devices used in clinics and hospitals
- Distributes products globally through eye care professionals and medical providers
Why it matters
Recurring medical needs
People need vision correction and fertility treatments year after year, which creates repeat demand.
How does The Cooper Companies, Inc. make money?
It earns revenue by selling high margin medical consumables that patients must regularly reorder.
- Contact lenses generate repeat purchases as they are disposable
- Women’s health products are sold to clinics for ongoing procedures
- Global distribution spreads revenue across many countries
Economic clue
60.7 percent gross margin
High gross margins suggest its products are differentiated enough to command strong pricing.
Why do long-term investors keep The Cooper Companies, Inc. on the radar?
It operates in healthcare categories tied to aging populations and long-term lifestyle trends.
- Rising global myopia rates increase the need for vision correction
- More women are seeking fertility treatments later in life
- Healthcare spending tends to be resilient even in recessions
Investor takeaway
Steady 5-year revenue growth of 8.8 percent
Consistent mid to high single digit growth over years signals structural demand rather than one-time spikes.
Based on company financial statements.
Benchmark Comparison
How has The Cooper Companies, Inc. performed against common long-term benchmarks?
Once the business case is clear, compare the stock against broad market and alternative long-term baselines.
$788.85
-21.1% total return
$1,753
+75.3% total return
$2,975
+197.5% total return
$1,393
+39.3% total return
| Asset | Total Return | Dollar Value |
|---|---|---|
| COO | -21.1% | $788.85 |
| S&P 500 | +75.3% | $1,753 |
| Gold | +197.5% | $2,975 |
| Bitcoin | +39.3% | $1,393 |
From Mar 5, 2021 to Mar 6, 2026. Historical price data based on company financial statements and market indices. Each card uses the same starting amount so the comparison stays apples-to-apples.
Investor Fit
How a first-time investor could frame The Cooper Companies, Inc.
Before going deeper, decide what kind of business this is, what it tends to suit, and what deserves monitoring over time.
This Can Fit If You Want
- Exposure to everyday healthcare products with repeat demand
- A business with 60.7 percent gross margins and solid cash conversion
- Steady growth around high single digits over many years
Be Careful If You Expect
- Fast double digit earnings growth every year
- Expanding margins without competitive pressure
- A high dividend payout, since it pays no dividend
What To Watch Over Time
- Whether operating margin stabilizes after recent contraction to 16.7 percent
- Long-term earnings per share growth after a weak five-year average
- Capital allocation discipline on acquisitions and buybacks
Key Metrics
Which metrics matter most for The Cooper Companies, Inc. right now?
Three durable business metrics that matter more than day-to-day price moves.
8.8 percent average annual growth over 5 years
Minus 57.9 percent average over 5 years
60.7 percent gross margin
| Metric | Value | Context |
|---|---|---|
| Revenue Growth | 8.8 percent average annual growth over 5 years | Shows whether the business has been expanding fast enough to create more long-term value. |
| EPS Growth | Minus 57.9 percent average over 5 years | Shows whether earnings per share are compounding for owners over time. |
| Margin Quality | 60.7 percent gross margin | Shows how much room the business has to fund growth, absorb shocks, and stay profitable. |
Based on company financial statements.
Fundamentals
What do The Cooper Companies, Inc.'s fundamentals say right now?
Core financial markers that explain how the business is performing beneath the stock price.
4.4% ROIC
60.7% gross margin
10.6% FCF margin
Stable to shrinking
| Metric | Value | Interpretation |
|---|---|---|
| Capital Efficiency | 4.4% ROIC | The business is currently showing poor capital efficiency. |
| Profitability | 60.7% gross margin | Healthy gross margins give the company room to invest, price competitively, and absorb shocks. |
| Cash Generation | 10.6% FCF margin | Free cash flow margin shows how much real cash the business keeps after funding operations and investment. |
| Ownership Trend | Stable to shrinking | The company is not currently diluting owners and may be buying back shares instead. |
Based on company financial statements.
Included In Funds
Which ETFs and funds currently hold The Cooper Companies, Inc.?
The Cooper Companies, Inc. currently appears in these ETF and fund proxies.
SPY
SPDR S&P 500 ETF Trust
IWB
iShares Russell 1000 ETF
Questions & Answers
What questions come up most often about The Cooper Companies, Inc.?
Company-specific questions readers often ask about The Cooper Companies, Inc..
Each entry answers a direct question about the business, the long-term thesis, or the risks that matter over time.
It makes and sells contact lenses and women’s health medical devices that doctors and patients use regularly.
Decision Framing
Secondary context after the long-term thesis
Shorter-horizon context and comparison tools, after the core long-term read.
Shorter-horizon price moves, two-sided debate, and comparison tools live here so the page stays anchored on business quality, durability, and BinaPrint fit first.
Investment Thesis
Bull vs Bear
Two-sided framing before any decision.
Current argument weight is balanced.
Bull case
What can work
Global myopia rates are rising, especially among younger populations, which could steadily increase the total number of contact lens wearers for decades.
Disposable contact lenses create built-in repeat purchases, making revenue more predictable than one-time device sales.
A 60.7 percent gross margin provides room to invest in research, marketing, and manufacturing while still generating cash.
Strong cash conversion, with free cash flow exceeding net income by 16 percent, supports reinvestment and shareholder returns.
Bear case
What can break
Intense competition in contact lenses could pressure pricing, pushing operating margin below the current 16.7 percent and permanently lowering profitability.
Technological shifts such as improved laser eye surgery or new vision correction methods could reduce long-term reliance on contact lenses.
Regulatory changes in healthcare reimbursement or medical device rules could increase compliance costs and reduce returns.
If fertility treatment demand slows due to policy changes or demographic shifts, part of the women’s health segment could stagnate.
Risk Radar
Key Risks
Where downside pressure can build.
Margin pressure risk: Operating margin at 16.7 percent is already contracting, and a sustained drop of 3 to 5 percentage points would meaningfully reduce net income.
Growth slowdown risk: Revenue grew 5.1 percent year over year, and if long-term growth falls below 5 percent, valuation support could weaken.
Capital intensity risk: 0.4 billion dollars in annual capital spending requires steady returns to justify ongoing investment.
Sizing matters
Risks should be read as scenario inputs, not certainties. Position size and time horizon determine how much of this downside profile is acceptable.
Market Snapshot
Tactical context after the core long-term read.
- Price
- $76.55
- Daily move
- -4.55%
Peer Set
A compact peer list for side-by-side context.
Next Actions
Explore planning scenarios or keep browsing similar companies.